Intas Pharmaceuticals
Ahmedabad, India
No confirmed program data — ClinicalTrials.gov verification pending
· Last scored 2026-09-07
51.4
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
○ Press
○ EMA GMP
✓ MHRA GMP (5)
Quick Facts: Intas Pharmaceuticals
- Signal Score
- 51.4/100 (as of 2026-09-07)
- Quality Compliance
- 45.5/100
- Headquarters
- Ahmedabad, India
- Modalities
- Cell Therapy
- Active Programs
- Data pending
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Intas Pharmaceuticals
Pure-play CDMO.
Signal Score & Pillar Breakdown
Scores are being republished.
Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.
Quality Compliance
45.5
FDA InspectionsNo US records on file
MHRA GMP Certificates5 on record
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCell Therapy
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Profile-based financial assessment
SEC FilingsPrivate company
Capacity
53.0
Profile-based capacity assessment
Intas Pharmaceuticals MHRA GMP Compliance 5 certificates
2025-03
2025-03
2024-02
2020-06
2018-01
Compliant
Non-Compliant
| Certificate | Site | City / Postcode | Inspection Date | Status |
|---|---|---|---|---|
| UK GMP 17543 Insp GMP 17543/9621-0025 [H] | INTAS PHARMACEUTICALS LIMITED | IN-382210 | 2025-03-06 | COMPLIANT |
| UK GMP 17543 Insp GMP 17543/9621-0025 [V] | INTAS PHARMACEUTICALS LIMITED | IN-382210 | 2025-03-06 | COMPLIANT |
| UK GMP 17543 Insp GMP 17543/13361605-0002[H] | INTAS PHARMACEUTICALS LIMITED | IN 248197 | 2024-02-01 | COMPLIANT |
| UK GMP 17543 Insp GMP 17543/18270974-0007[H] | INTAS PHARMACEUTICALS LIMITED | IN 382213 | 2020-06-23 | COMPLIANT |
| UK GMP 17543 Insp GMP 17543/1682029-0005[H] | INTAS PHARMACEUTICALS LIMITED | IN-382213 | 2018-01-29 | COMPLIANT |
Source: MHRA GMDP Database · Retrieved Oct 06, 2026
Frequently Asked Questions About Intas Pharmaceuticals
Does Intas Pharmaceuticals hold EMA or MHRA GMP certificates?
CDMO Signal tracks 5 MHRA GMP certificates for Intas Pharmaceuticals.
What is Intas Pharmaceuticals's CDMO Signal Score?
Intas Pharmaceuticals has a Signal Score of 51/100, based on quality, operations, financial stability, and capacity data.
Evaluating Intas Pharmaceuticals for a manufacturing program?
Use the free AI matchmaker to compare Intas Pharmaceuticals against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Syngene International
Bengaluru, India
Signal Score: 78.5
Biologics, Cell Therapy
Biocon Biologics
Bengaluru, India
Signal Score: 77.6
Cell Therapy
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 91.1
CAR-T, Cell Therapy
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 90.9
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 83.9
CAR-T, Cell Therapy